Condition: PDL1 Gene Mutation · Non Small Cell Lung Cancer · Small Cell Lung Cancer ( SCLC ) · Sponsor: Radiopharm Theranostics, Ltd
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability, biodistribution, radiation dosimetry and preliminary anti-tumour activities of 177Lu-RAD204 in participants with selected solid tumours, to identify the MTDs/ recommended doses of 177Lu-RAD204 for future exploration. The study will consist of a Pre-screening Period (if applicable for PD-L1 testing), a Screening Period of up to 4 weeks, followed by a Phase 0 (Imaging) Period for imaging and dosimetry to 177Lu-RAD204im and a Phase I (Treatment) Period for 177Lu-RAD204tr dose escalation.
This description comes directly from the study's public registry record.
Dimitris Voliotis, MD · +1 646 535 5017 · dv@radiopharmtheranostics.com
Always discuss trial participation with your own doctor first.
| Nepean Hospital | Kingswood, New South Wales, Australia | Recruiting |
| Wollongong Hospital | Wollongong, New South Wales, Australia | Recruiting |
| Gold Coast University Hospital | Southport, Queensland, Australia | Recruiting |
| Cancer Research SA (CRSA) | Adelaide, South Australia, Australia | Recruiting |
| GenesisCare Murdoch | Murdoch, Western Australia, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06305962